BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Eosinophilic esophagitis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for eosinophilic esophagitis: 11 (8 sponsors; 0 newly posted in the last 180 days, 0 stopped in the last 180 days; 0 new-entrant sponsors). Momentum score 13.6, rank 50 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 0, Phase 2 4, Phase 3 3, Phase 4 1, N/A 3.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Regeneron Pharmaceuticals REGN | 3 | P2 1, NA 1, P3 1 | 0 | 0 |
| AstraZeneca AZN | 1 | P3 1 | 0 | 0 |
| Dr. Falk Pharma GmbH | 1 | P3 1 | 0 | 1 |
| Sanofi SNY | 2 | NA 1, P4 1 | 0 | 0 |
| Eupraxia Pharmaceuticals Inc. EPRX | 1 | P2 1 | 0 | 1 |
| Kate Farms Inc | 1 | NA 1 | 0 | 0 |
| Phathom Pharmaceuticals, Inc. PHAT | 1 | P2 1 | 0 | 0 |
| Uniquity One (UNI) | 1 | P2 1 | 0 | 1 |
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | Eupraxia Pharmaceuticals Inc. EPRX | NCT05608681 A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). | Eosinophilic Esophagitis | recruiting | 117 |
| 2026-12 est. | P2 | NS Pharma, Inc. | NCT06046222 Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | Eosinophilic Granulomatosis With Polyangiitis; Churg-Strauss Syndrome | active not recruiting | 45 |
| 2026-12 est. | P3 | Dr. Falk Pharma GmbH | NCT06596252 Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | Eosinophilic Esophagitis | active not recruiting | 308 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-06 | P3 | GlaxoSmithKline | NCT05263934 Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Eosinophilic Granulomatosis With Polyangiitis | completed | 163 |
| 2026-10 est. | P2 | Advagene Biopharma Co. Ltd. | NCT07250594 A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma | Eosinophilic Asthma | not yet recruiting | 126 |
| 2026-09-21 | P3 | AstraZeneca AZN | NCT06750289 Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated | Eosinophilic Asthma | completed | 130 |
| 2026-09-11 | P2 | Phathom Pharmaceuticals, Inc. PHAT | NCT06851559 A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks | Eosinophilic Esophagitis | active not recruiting | 95 |
| 2026-07-14 | P3 | AstraZeneca AZN | NCT05583227 Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | active not recruiting | 368 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "eosinophilic esophagitis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.